(San Francisco) -- Mytrus, an innovative clinical technology and services company for medical and pharmaceutical research, today announced that Anthony J. Costello has been appointed company CEO, effective immediately. He replaces Steve Cummings, MD, who is now the company's new chief scientific officer and who will remain as chairman of the board of directors.
"Mytrus is experiencing significant growth through the addition of new sponsors, partners and a greater number of ongoing clinical studies," Cummings said. "Going forward, I will be concentrating on the more scientific aspects of our business and ensuring that Mytrus achieves its mission: to enable people to safely participate in clinical trials from the convenience of their homes or in the field. Anthony will be responsible for the business aspects related to Mytrus as we broaden our customer base and product line for conducting direct-to-patient data clinical studies."
Costello is one of the founding members of Mytrus and previously served as its chief operating officer. Before joining the company in 2009, he co-founded Nextrials, Inc. and served as its vice president of product development; he also served for several years as manager of oncology clinical data management at Genentech, Inc. He is a past chairman of the board of trustees for the Society of Clinical Data Management and a member of the editorial advisory board for Applied Clinical Trials magazine. He holds a degree in sociology from the University of California at Berkeley.
The recipient of numerous awards, Cummings is recognized as an expert in the methodology for conducting clinical research. He is an elected member of the Institute of Medicine in the National Academy of Science, and is known for his leadership and studies in the areas of osteoporosis and aging. He is an emeritus Professor of Medicine and Epidemiology from the University of California, San Francisco and is a director of the San Francisco Coordinating Center.
Founded in 2009, Mytrus is a California-based clinical technology and services company which is revolutionizing traditional clinical trials with its simple, efficient, and patient-centered technologies. Creating interactive tools which improve patient comprehension and comfort, Mytrus streamlines the clinical trial process, dramatically improving patient recruitment timelines, increasing patient retention and reducing overall study costs for sponsors. At a time when bringing a drug to market can cost up to $1 billion, Mytrus provides solutions for pharmaceutical, biotech and device makers eager to find more cost effective ways to conduct research. Mytrus is partially owned by inVentiv Health, a global life science knowledge and services company innovating for the new health care environment.